965 related articles for article (PubMed ID: 20088621)
21. Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine.
Rodda J; Morgan S; Walker Z
Int Psychogeriatr; 2009 Oct; 21(5):813-24. PubMed ID: 19538824
[TBL] [Abstract][Full Text] [Related]
22. Effectiveness and safety of cholinesterase inhibitors in elderly subjects with Alzheimer's disease: a "real world" study.
Mossello E; Tonon E; Caleri V; Tilli S; Cantini C; Cavallini MC; Bencini F; Mecacci R; Marini M; Bardelli F; Sarcone E; Razzi E; Biagini CA; Masotti G
Arch Gerontol Geriatr Suppl; 2004; (9):297-307. PubMed ID: 15207427
[TBL] [Abstract][Full Text] [Related]
23. Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis.
Battle CE; Abdul-Rahim AH; Shenkin SD; Hewitt J; Quinn TJ
Cochrane Database Syst Rev; 2021 Feb; 2(2):CD013306. PubMed ID: 33704781
[TBL] [Abstract][Full Text] [Related]
24. A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease.
Jones RW; Soininen H; Hager K; Aarsland D; Passmore P; Murthy A; Zhang R; Bahra R
Int J Geriatr Psychiatry; 2004 Jan; 19(1):58-67. PubMed ID: 14716700
[TBL] [Abstract][Full Text] [Related]
25. Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease: Three Randomized Clinical Trials.
Atri A; Frölich L; Ballard C; Tariot PN; Molinuevo JL; Boneva N; Windfeld K; Raket LL; Cummings JL
JAMA; 2018 Jan; 319(2):130-142. PubMed ID: 29318278
[TBL] [Abstract][Full Text] [Related]
26. Acetylcholinesterase inhibitors and sleep architecture in patients with Alzheimer's disease.
Cooke JR; Loredo JS; Liu L; Marler M; Corey-Bloom J; Fiorentino L; Harrison T; Ancoli-Israel S
Drugs Aging; 2006; 23(6):503-11. PubMed ID: 16872233
[TBL] [Abstract][Full Text] [Related]
27. A longitudinal study of risk factors for community-based home help services in Alzheimer's disease: the influence of cholinesterase inhibitor therapy.
Wattmo C; Paulsson E; Minthon L; Londos E
Clin Interv Aging; 2013; 8():329-39. PubMed ID: 23682212
[TBL] [Abstract][Full Text] [Related]
28. Differential effects of current specific treatments on behavioral and psychological symptoms in patients with Alzheimer's disease: a 12-month, randomized, open-label trial.
Cumbo E; Ligori LD
J Alzheimers Dis; 2014; 39(3):477-85. PubMed ID: 24164733
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.
Tan CC; Yu JT; Wang HF; Tan MS; Meng XF; Wang C; Jiang T; Zhu XC; Tan L
J Alzheimers Dis; 2014; 41(2):615-31. PubMed ID: 24662102
[TBL] [Abstract][Full Text] [Related]
30. [Retrospective comparative analysis of antidementia medication persistence patterns in Spanish Alzheimer's disease patients treated with donepezil, rivastigmine, galantamine and memantine].
Sicras-Mainar A; Vergara J; Leon-Colombo T; Febrer L; Rejas-Gutierrez J
Rev Neurol; 2006 Oct 16-31; 43(8):449-53. PubMed ID: 17033976
[TBL] [Abstract][Full Text] [Related]
31. APOE-ɛ4 Carrier Status and Donepezil Response in Patients with Alzheimer's Disease.
Waring JF; Tang Q; Robieson WZ; King DP; Das U; Dubow J; Dutta S; Marek GJ; Gault LM
J Alzheimers Dis; 2015; 47(1):137-48. PubMed ID: 26402762
[TBL] [Abstract][Full Text] [Related]
32. [Drug-cholinesterase-inhibitors persistence patterns in treated patients with dementia of Alzheimer type: retrospective comparative analysis of donepezil, rivastigmine and galantamine].
Sicras A; Rejas-Gutiérrez J
Rev Neurol; 2004 Aug 16-31; 39(4):312-6. PubMed ID: 15340887
[TBL] [Abstract][Full Text] [Related]
33. FOXO1 locus and acetylcholinesterase inhibitors in elderly patients with Alzheimer's disease.
Paroni G; Seripa D; Fontana A; D'Onofrio G; Gravina C; Urbano M; Cascavilla L; Pellegrini F; Greco A; Pilotto A
Clin Interv Aging; 2014; 9():1783-91. PubMed ID: 25364236
[TBL] [Abstract][Full Text] [Related]
34. Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease.
Blesa R; Bullock R; He Y; Bergman H; Gambina G; Meyer J; Rapatz G; Nagel J; Lane R
Pharmacogenet Genomics; 2006 Nov; 16(11):771-4. PubMed ID: 17047484
[TBL] [Abstract][Full Text] [Related]
35. The comparative efficacy and safety of cholinesterase inhibitors in patients with mild-to-moderate Alzheimer's disease: a Bayesian network meta-analysis.
Kobayashi H; Ohnishi T; Nakagawa R; Yoshizawa K
Int J Geriatr Psychiatry; 2016 Aug; 31(8):892-904. PubMed ID: 26680338
[TBL] [Abstract][Full Text] [Related]
36. Response to rivastigmine transdermal patch or memantine plus rivastigmine patch is affected by apolipoprotein E genotype in Alzheimer patients.
Han HJ; Kim BC; Lee JY; Ryu SH; Na HR; Yoon SJ; Park HY; Shin JH; Cho SJ; Yi HA; Choi MS; Heo JH; Park KW; Kim KK; Choi SH
Dement Geriatr Cogn Disord; 2012; 34(3-4):167-73. PubMed ID: 23051684
[TBL] [Abstract][Full Text] [Related]
37. Two galantamine titration regimens in patients switched from donepezil.
Engedal K; Davis B; Richarz U; Han J; Schäuble B; Andreasen N
Acta Neurol Scand; 2012 Jul; 126(1):37-44. PubMed ID: 21992111
[TBL] [Abstract][Full Text] [Related]
38. Galantamine provides sustained benefits in patients with 'advanced moderate' Alzheimer's disease for at least 12 months.
Blesa R; Davidson M; Kurz A; Reichman W; van Baelen B; Schwalen S
Dement Geriatr Cogn Disord; 2003; 15(2):79-87. PubMed ID: 12566596
[TBL] [Abstract][Full Text] [Related]
39. Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials.
Kaduszkiewicz H; Zimmermann T; Beck-Bornholdt HP; van den Bussche H
BMJ; 2005 Aug; 331(7512):321-7. PubMed ID: 16081444
[TBL] [Abstract][Full Text] [Related]
40. Donepezil for vascular cognitive impairment.
Malouf R; Birks J
Cochrane Database Syst Rev; 2004; (1):CD004395. PubMed ID: 14974068
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]